These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

562 related articles for article (PubMed ID: 18955864)

  • 1. Liver disease associated with ZZ alpha1-antitrypsin deficiency and ursodeoxycholic acid therapy in children.
    Lykavieris P; Ducot B; Lachaux A; Dabadie A; Broué P; Sarles J; Bernard O; Jacquemin E
    J Pediatr Gastroenterol Nutr; 2008 Nov; 47(5):623-9. PubMed ID: 18955864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis.
    Jacquemin E; Hermans D; Myara A; Habes D; Debray D; Hadchouel M; Sokal EM; Bernard O
    Hepatology; 1997 Mar; 25(3):519-23. PubMed ID: 9049190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis.
    Colombo C; Battezzati PM; Podda M; Bettinardi N; Giunta A
    Hepatology; 1996 Jun; 23(6):1484-90. PubMed ID: 8675168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ursodeoxycholic acid treatment in isolated chronic graft-vs.-host disease of the liver.
    Arat M; Idilman R; Soydan EA; Soykan I; Erden E; Karayalçin S; Akan H
    Clin Transplant; 2005 Dec; 19(6):798-803. PubMed ID: 16313328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study.
    Laurin J; Lindor KD; Crippin JS; Gossard A; Gores GJ; Ludwig J; Rakela J; McGill DB
    Hepatology; 1996 Jun; 23(6):1464-7. PubMed ID: 8675165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of ursodeoxycholic acid on serum liver enzymes in patients with hepatitis C virus-related chronic liver disease.
    Puoti C; Magrini A; Filippi T; Annovazzi G; Pannullo A
    Eur J Gastroenterol Hepatol; 1995 Feb; 7(2):151-4. PubMed ID: 7712308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ursodeoxycholic acid therapy for intractable total parenteral nutrition-associated cholestasis in surgical very low birth weight infants.
    Al-Hathlol K; Al-Madani A; Al-Saif S; Abulaimoun B; Al-Tawil K; El-Demerdash A
    Singapore Med J; 2006 Feb; 47(2):147-51. PubMed ID: 16435058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha-1-antitrypsin deficiency in children: liver disease is not reflected by low serum levels of alpha-1-antitrypsin - a study on 48 pediatric patients.
    Lang T; Mühlbauer M; Strobelt M; Weidinger S; Hadorn HB
    Eur J Med Res; 2005 Dec; 10(12):509-14. PubMed ID: 16356865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ursodeoxycholic acid and artesunate in the treatment of severe falciparum malaria patients with jaundice.
    Treeprasertsuk S; Silachamroon U; Krudsood S; Huntrup A; Suwannakudt P; Vannaphan S; Wilairatana P
    J Gastroenterol Hepatol; 2010 Feb; 25(2):362-8. PubMed ID: 19817958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis.
    Bonnand AM; Heathcote EJ; Lindor KD; Poupon RE
    Hepatology; 1999 Jan; 29(1):39-43. PubMed ID: 9862847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The liver in 30-year-old individuals with alpha(1)-antitrypsin deficiency.
    Bernspång E; Carlson J; Piitulainen E
    Scand J Gastroenterol; 2009; 44(11):1349-55. PubMed ID: 19891586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Long-term ursodeoxycholic acid treatment of cholestatic liver diseases in childhood--clinical and biochemical effects].
    Kardorff R; Melter M; Rodeck B; Brodehl J
    Klin Padiatr; 1996; 208(3):118-22. PubMed ID: 8676599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.
    Kuiper EM; Hansen BE; de Vries RA; den Ouden-Muller JW; van Ditzhuijsen TJ; Haagsma EB; Houben MH; Witteman BJ; van Erpecum KJ; van Buuren HR;
    Gastroenterology; 2009 Apr; 136(4):1281-7. PubMed ID: 19208346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of ursodeoxycholic acid on liver function in children after successful surgery for biliary atresia.
    Willot S; Uhlen S; Michaud L; Briand G; Bonnevalle M; Sfeir R; Gottrand F
    Pediatrics; 2008 Dec; 122(6):e1236-41. PubMed ID: 19029197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The benign course of liver disease in adults with cystic fibrosis and the effect of ursodeoxycholic acid.
    Desmond CP; Wilson J; Bailey M; Clark D; Roberts SK
    Liver Int; 2007 Dec; 27(10):1402-8. PubMed ID: 18036103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ursodeoxycholic therapy in chronic liver disease: a meta-analysis in primary biliary cirrhosis and in chronic hepatitis.
    Simko V; Michael S; Prego V
    Am J Gastroenterol; 1994 Mar; 89(3):392-8. PubMed ID: 8122652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocellular carcinoma and liver cirrhosis: assessment of the liver function after Yttrium-90 radioembolization with resin microspheres or after CT-guided high-dose-rate brachytherapy.
    Rühl R; Seidensticker M; Peters N; Mohnike K; Bornschein J; Schütte K; Amthauer H; Malfertheiner P; Pech M; Ricke J
    Dig Dis; 2009; 27(2):189-99. PubMed ID: 19546558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. A 12-year experience.
    Zapata R; Sandoval L; Palma J; Hernández I; Ribalta J; Reyes H; Sedano M; Tohá D; Silva JJ
    Liver Int; 2005 Jun; 25(3):548-54. PubMed ID: 15910492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variable degree of liver involvement in siblings with PiZZ alpha-1-antitrypsin deficiency-related liver disease.
    Hinds R; Hadchouel A; Shanmugham NP; Al-Hussaini A; Chambers S; Cheeseman P; Mieli-Vergani G; Hadzić N
    J Pediatr Gastroenterol Nutr; 2006 Jul; 43(1):136-8. PubMed ID: 16819392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis.
    Corpechot C; Poujol-Robert A; Wendum D; Galotte M; Chrétien Y; Poupon RE; Poupon R
    Liver Int; 2004 Jun; 24(3):187-93. PubMed ID: 15189267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.